Minor stroke/TIA: ticagrelor-aspirin edges out clopidogrel-aspirin

  • Wang Y & al.
  • BMJ
  • 6 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Among patients with minor stroke or transient ischemic attack (TIA), ticagrelor (Brilinta) plus aspirin was superior to clopidogrel (Plavix) plus aspirin in reducing high platelet reactivity and, among those with large-artery atherosclerosis, recurrent stroke risk.

Why this matters

Key results

  • 90-day high platelet reactivity less common with ticagrelor-aspirin vs clopidogrel-aspirin:
    • In trial population (12.5% vs 29.7%; risk ratio, 0.40; P<.001>
    • In subgroup carrying CYP2C19 loss-of-function alleles (10.8% vs 35.4%; risk ratio, 0.31; P<.001>
  • 90-day incidence of recurrent stroke:
    • Similar in trial population (6.3% vs 8.8%; HR, 0.70; P=.20),
    • Lower with ticagrelor-aspirin in subgroup with large-artery atherosclerosis (6.0% vs 13.1%; HR, 0.45; P=.04).
  • Similar rate of major or minor bleeding (4.8% vs 3.5%; P=.42).

Study design

  • Chinese phase 2 randomized controlled trial: 675 patients with minor stroke or TIA (PRINCE trial).
  • Randomization: open-label ticagrelor vs clopidogrel, plus aspirin within 24 hours of symptom onset.
  • Main outcome: high platelet reactivity.
  • Funding: Ministry of Science and Technology of People’s Republic of China; others. AstraZeneca (study drugs).

Limitations

  • High platelet reactivity a surrogate.
  • Underpowered for clinical events.
  • Lack of blinding.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit